FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912706686> ?p ?o ?g. }

• W2912706686 endingPage "60.e11" @default.
• W2912706686 startingPage "51" @default.
• W2912706686 abstract "BackgroundImproved diagnostic tools for predicting future exacerbation frequency in asthmatic patients are required. A sputum gene expression signature of 6 biomarkers (6-gene signature [6GS], including Charcot-Leyden crystal galectin [CLC]; carboxypeptidase 3 [CPA3]; deoxyribonuclease 1-like 3 [DNASE1L3]; alkaline phosphatase, liver/bone/kidney [ALPL]; CXCR2; and IL1B) predicts inflammatory and treatment response phenotypes in patients with stable asthma. Recently, we demonstrated that azithromycin (AZM) add-on treatment in patients with uncontrolled moderate-to-severe asthma significantly reduced asthma exacerbations (AMAZES clinical trial).ObjectivesWe sought to test whether the 6GS predicts future exacerbation and inflammatory phenotypes in a subpopulation of AMAZES and to test the effect of AZM therapy on 6GS expression and prognostic capacity.MethodsOne hundred forty-two patients (73 placebo-treated and 69 AZM-treated patients) had sputum stored for quantitative PCR of 6GS markers at baseline and after 48 weeks of treatment. Logistic regression and receiver operating characteristic and area under the curve (AUC) determination were performed on baseline measures, and in an exploratory analysis the predictive value of the 6GS was compared with conventional biomarkers for exacerbation and inflammatory phenotypes.ResultsThe 6GS significantly predicted all future exacerbation phenotypes tested. Calculated AUCs for the 6GS were significantly greater than AUCs for peripheral blood eosinophil counts, sputum neutrophil counts, and combined sputum eosinophil and neutrophil counts. 6GS AUCs were also numerically but not significantly greater than those for fractional exhaled nitric oxide values and sputum eosinophil counts. AZM treatment altered neither 6GS expression nor the predictive capacity of the 6GS for future exacerbation phenotypes. The 6GS was a significant predictor of airway inflammatory phenotype in this population.ConclusionWe demonstrate that a sputum gene signature can predict future exacerbation phenotypes of asthma, with the greatest biomarker performance in identifying those who would experience frequent severe exacerbations. AZM therapy did not modify 6GS expression or biomarker performance, suggesting the therapeutic action of AZM is independent of 6GS-related inflammatory pathways. Improved diagnostic tools for predicting future exacerbation frequency in asthmatic patients are required. A sputum gene expression signature of 6 biomarkers (6-gene signature [6GS], including Charcot-Leyden crystal galectin [CLC]; carboxypeptidase 3 [CPA3]; deoxyribonuclease 1-like 3 [DNASE1L3]; alkaline phosphatase, liver/bone/kidney [ALPL]; CXCR2; and IL1B) predicts inflammatory and treatment response phenotypes in patients with stable asthma. Recently, we demonstrated that azithromycin (AZM) add-on treatment in patients with uncontrolled moderate-to-severe asthma significantly reduced asthma exacerbations (AMAZES clinical trial). We sought to test whether the 6GS predicts future exacerbation and inflammatory phenotypes in a subpopulation of AMAZES and to test the effect of AZM therapy on 6GS expression and prognostic capacity. One hundred forty-two patients (73 placebo-treated and 69 AZM-treated patients) had sputum stored for quantitative PCR of 6GS markers at baseline and after 48 weeks of treatment. Logistic regression and receiver operating characteristic and area under the curve (AUC) determination were performed on baseline measures, and in an exploratory analysis the predictive value of the 6GS was compared with conventional biomarkers for exacerbation and inflammatory phenotypes. The 6GS significantly predicted all future exacerbation phenotypes tested. Calculated AUCs for the 6GS were significantly greater than AUCs for peripheral blood eosinophil counts, sputum neutrophil counts, and combined sputum eosinophil and neutrophil counts. 6GS AUCs were also numerically but not significantly greater than those for fractional exhaled nitric oxide values and sputum eosinophil counts. AZM treatment altered neither 6GS expression nor the predictive capacity of the 6GS for future exacerbation phenotypes. The 6GS was a significant predictor of airway inflammatory phenotype in this population. We demonstrate that a sputum gene signature can predict future exacerbation phenotypes of asthma, with the greatest biomarker performance in identifying those who would experience frequent severe exacerbations. AZM therapy did not modify 6GS expression or biomarker performance, suggesting the therapeutic action of AZM is independent of 6GS-related inflammatory pathways." @default.
• W2912706686 created "2019-02-21" @default.
• W2912706686 creator A5002958668 @default.
• W2912706686 creator A5003618898 @default.
• W2912706686 creator A5015624407 @default.
• W2912706686 creator A5024470634 @default.
• W2912706686 creator A5035806248 @default.
• W2912706686 creator A5039913549 @default.
• W2912706686 creator A5040155950 @default.
• W2912706686 creator A5047181213 @default.
• W2912706686 creator A5048322411 @default.
• W2912706686 creator A5061854724 @default.
• W2912706686 creator A5072697342 @default.
• W2912706686 creator A5074160945 @default.
• W2912706686 creator A5078153354 @default.
• W2912706686 creator A5079262837 @default.
• W2912706686 date "2019-07-01" @default.
• W2912706686 modified "2023-10-15" @default.
• W2912706686 title "A sputum 6-gene signature predicts future exacerbations of poorly controlled asthma" @default.
• W2912706686 cites W1964669406 @default.
• W2912706686 cites W1978995149 @default.
• W2912706686 cites W1989626763 @default.
• W2912706686 cites W1995033048 @default.
• W2912706686 cites W2013105339 @default.
• W2912706686 cites W2015105473 @default.
• W2912706686 cites W2023836642 @default.
• W2912706686 cites W2024585538 @default.
• W2912706686 cites W2029834141 @default.
• W2912706686 cites W2053208368 @default.
• W2912706686 cites W2072619523 @default.
• W2912706686 cites W2080317016 @default.
• W2912706686 cites W2098276532 @default.
• W2912706686 cites W2100107417 @default.
• W2912706686 cites W2105881664 @default.
• W2912706686 cites W2108919922 @default.
• W2912706686 cites W2111609315 @default.
• W2912706686 cites W2120277552 @default.
• W2912706686 cites W2127303736 @default.
• W2912706686 cites W2136241314 @default.
• W2912706686 cites W2145370817 @default.
• W2912706686 cites W2146887625 @default.
• W2912706686 cites W2154263136 @default.
• W2912706686 cites W2158490560 @default.
• W2912706686 cites W2162313549 @default.
• W2912706686 cites W2277425553 @default.
• W2912706686 cites W2347163170 @default.
• W2912706686 cites W2517035143 @default.
• W2912706686 cites W2586238008 @default.
• W2912706686 cites W2586700856 @default.
• W2912706686 cites W2594842120 @default.
• W2912706686 cites W2601675613 @default.
• W2912706686 cites W2605678322 @default.
• W2912706686 cites W2611177496 @default.
• W2912706686 cites W2728465556 @default.
• W2912706686 cites W2728759164 @default.
• W2912706686 cites W2730218169 @default.
• W2912706686 cites W2754857446 @default.
• W2912706686 doi "https://doi.org/10.1016/j.jaci.2018.12.1020" @default.
• W2912706686 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30682452" @default.
• W2912706686 hasPublicationYear "2019" @default.
• W2912706686 type Work @default.
• W2912706686 sameAs 2912706686 @default.
• W2912706686 citedByCount "44" @default.
• W2912706686 countsByYear W29127066862019 @default.
• W2912706686 countsByYear W29127066862020 @default.
• W2912706686 countsByYear W29127066862021 @default.
• W2912706686 countsByYear W29127066862022 @default.
• W2912706686 countsByYear W29127066862023 @default.
• W2912706686 crossrefType "journal-article" @default.
• W2912706686 hasAuthorship W2912706686A5002958668 @default.
• W2912706686 hasAuthorship W2912706686A5003618898 @default.
• W2912706686 hasAuthorship W2912706686A5015624407 @default.
• W2912706686 hasAuthorship W2912706686A5024470634 @default.
• W2912706686 hasAuthorship W2912706686A5035806248 @default.
• W2912706686 hasAuthorship W2912706686A5039913549 @default.
• W2912706686 hasAuthorship W2912706686A5040155950 @default.
• W2912706686 hasAuthorship W2912706686A5047181213 @default.
• W2912706686 hasAuthorship W2912706686A5048322411 @default.
• W2912706686 hasAuthorship W2912706686A5061854724 @default.
• W2912706686 hasAuthorship W2912706686A5072697342 @default.
• W2912706686 hasAuthorship W2912706686A5074160945 @default.
• W2912706686 hasAuthorship W2912706686A5078153354 @default.
• W2912706686 hasAuthorship W2912706686A5079262837 @default.
• W2912706686 hasBestOaLocation W29127066861 @default.
• W2912706686 hasConcept C126322002 @default.
• W2912706686 hasConcept C142724271 @default.
• W2912706686 hasConcept C203014093 @default.
• W2912706686 hasConcept C2776042228 @default.
• W2912706686 hasConcept C2776301714 @default.
• W2912706686 hasConcept C2777014857 @default.
• W2912706686 hasConcept C2777037409 @default.
• W2912706686 hasConcept C2780333948 @default.
• W2912706686 hasConcept C2781069245 @default.
• W2912706686 hasConcept C2781142857 @default.
• W2912706686 hasConcept C71924100 @default.
• W2912706686 hasConcept C90924648 @default.
• W2912706686 hasConceptScore W2912706686C126322002 @default.
• W2912706686 hasConceptScore W2912706686C142724271 @default.

• next